. NUT midline carcinoma (NMC), with a median survival of 6.7 months, is one of the most aggressive solid tumors known. It is a subtype of squamous cell carcinoma characterized by translocation of the NUT (aka NUTM1) gene, most commonly forming a fusion to the double-bromodomain encoding protein (BET), BRD4. There is an urgent need for the identification of more specific therapeutic targets in NMC. The over-reaching goal of this proposed project is to greater understand the mechanism of BRD4-NUT oncogenesis and identify effective therapeutic targets for treating this disease. BRD4-NUT functions to block differentiation and maintain proliferation of NMC cells, largely through activation of MYC expression. This function is disrupted upon treatment with BET inhibitors, which as acetyl- lysine mimetics prevent binding of BRD4 bromodomains to acetylated chromatin. BRD4-NUT drives the expression of pro-growth target genes, including MYC, through the formation of megabase-sized massive hyperacetylated 'megadomains'. BRD4-NUT megadomains arise from pre-existing active enhancers and spread to fill cell-type-specific topologically associating domains (TADs). TADs are higher order genomic structures whose function is to orchestrate cell-fate determining transcriptional programs through DNA-DNA contacts. Unique proteins recruited by BRD4-NUT recently identified by our group include the histone acetyl- transferase (HAT), p300, and several ZNF proteins collectively termed Z4. These findings indicate that BRD4- NUT ?hijacks? cell-type specific TADs to drive transcription of pro-growth, anti-differentiative genes as postulated in the following model: First, BRD4-NUT complex proteins seed regions corresponding to cell-type- specific active TADs through the chromatin-binding of BRD4. Second, megadomains form from contiguous expansion of BRD4-NUT complexes across chromatin in a feed-forward manner dependent upon p300 HAT activity. Third, megadomain size is limited by TAD boundaries and HDAC activity recruited by the Z4 complex. Fourth, hyperacetylated chromatin, recruitment of chromatin remodelers, and upregulation of cis lncRNAs changes the chromatin configuration to enhance DNA-DNA interactions to drive transcription of key pro- growth, anti-differentiative genes. The goals of this proposal are to test this hypothetical model, as listed in the specific aims below.
Aim 1. To determine how BRD4-NUT megadomains form.
Aim 2. To determine how BRD4-NUT megadomains function. Impact. Successful completion of the aims is expected to identify key BRD4-NUT-associated proteins in pathologic megadomain formation, and will identify novel and possibly more effective therapeutic targets in NMC and other cancers. In addition, we predict that BRD4-NUT megadomains will provide a model with far- reaching impact on the structure-function relationship of chromatin conformation in cancer and development.
French, Christopher, Alexander Project Narrative NUT midline carcinoma is an incurable highly aggressive cancer with a median survival of 6.7 months. The causative oncoprotein, BRD4-NUT, drives aberrant oncogene target expression through formation of megabase-sized contiguous BRD4-NUT and acetyl-histone enriched chromatin, termed megadomains. The project, which is to determine how megadomains form and function will reveal fundamental principles of how chromatin conformation can be manipulated in a novel cancer mechanism, and identify novel therapeutic cancer targets. PHS 398/2590 (Rev. 09/04) Page Continuation Format Page
|Shiota, Hitoshi; Elya, Janine E; Alekseyenko, Artyom A et al. (2018) ""Z4"" Complex Member Fusions in NUT Carcinoma: Implications for a Novel Oncogenic Mechanism. Mol Cancer Res 16:1826-1833|
|Agaimy, Abbas; Fonseca, Isabel; Martins, Carmo et al. (2018) NUT Carcinoma of the Salivary Glands: Clinicopathologic and Molecular Analysis of 3 Cases and a Survey of NUT Expression in Salivary Gland Carcinomas. Am J Surg Pathol 42:877-884|
|Alekseyenko, Artyom A; Walsh, Erica M; Zee, Barry M et al. (2017) Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma. Proc Natl Acad Sci U S A 114:E4184-E4192|
|Hellquist, Henrik; French, Christopher A; Bishop, Justin A et al. (2017) NUT midline carcinoma of the larynx: an international series and review of the literature. Histopathology 70:861-868|
|Chau, Nicole G; Hurwitz, Shelley; Mitchell, Chelsey M et al. (2016) Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck. Cancer 122:3632-3640|
|Stathis, Anastasios; Zucca, Emanuele; Bekradda, Mohamed et al. (2016) Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628. Cancer Discov 6:492-500|
|Sholl, Lynette M; Nishino, Mizuki; Pokharel, Saraswati et al. (2015) Primary Pulmonary NUT Midline Carcinoma: Clinical, Radiographic, and Pathologic Characterizations. J Thorac Oncol 10:951-9|
|Alekseyenko, Artyom A; Walsh, Erica M; Wang, Xin et al. (2015) The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains. Genes Dev 29:1507-23|
|French, Christopher A; Rahman, Shaila; Walsh, Erica M et al. (2014) NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism. Cancer Discov 4:928-41|
|Puliyel, Mammen M; Mascarenhas, Leo; Zhou, Shengmei et al. (2014) Nuclear protein in testis midline carcinoma misdiagnosed as adamantinoma. J Clin Oncol 32:e57-60|
Showing the most recent 10 out of 22 publications